Psyence Biomedical (PBM) Net Income towards Common Stockholders (2023 - 2025)

Psyence Biomedical's Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at -$1.5 million for Q3 2025.

• On a quarterly basis, Net Income towards Common Stockholders fell 1163.79% year-over-year to -$1.5 million in Q3 2025; TTM through Mar 2026 was -$1.4 million, a 710.6% decrease from a year earlier, with the FY2026 full-year figure at -$6.2 million, down 70.34% from the prior year.
• Net Income towards Common Stockholders eased to -$1.5 million in Q3 2025 per PBM's latest filing, from $141473.0 in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $141473.0 in Q3 2024 and bottomed at -$3.2 million in Q1 2023.
• The 3-year median for Net Income towards Common Stockholders is -$907329.5 (2023), against an average of -$1.2 million.
• Across the five-year window, Net Income towards Common Stockholders soared 145.68% in 2024 and plunged 1163.79% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$309682.0 in 2023, then surged by 145.68% to $141473.0 in 2024, then plunged by 1163.79% to -$1.5 million in 2025.
• Per Business Quant, the three latest PBM Net Income towards Common Stockholders figures stand at -$1.5 million (Q3 2025), $141473.0 (Q3 2024), and -$309682.0 (Q3 2023).